MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinomaMUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
|
| 0 Comment
Epidermal development issue receptor tyrosine kinase inhibitors (EGFR-TKIs) are efficient in sufferers with non-small cell lung most cancers (NSCLC) harboring EGFR mutations. Nevertheless, as a result of acquired resistance to